SCHEMBL4155325

SCHEMBL4155325

NC(=O)c1ccc(Oc2cccc(F)c2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
USP2 O75604 1/20 0.44
KMT2A Q03164 1/20 0.44
PARP1 P09874 1/20 0.44
CDC7 O00311 1/20 0.43
DYRK3 O43781 1/20 0.43
ROCK2 O75116 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
CDK1 P06493 1/20 0.43
PIM1 P11309 1/20 0.43
PRKACA P17612 1/20 0.43
CDK2 P24941 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
FRK P42685 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CSNK1D P48730 1/20 0.43
CLK2 P49760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155326 0.81 PARP10 (0.50) ALDH1A1MAPTPARP10NPSR1SLC9A1
SCHEMBL4152606 0.77 SLC9A1 (0.40) ALDH1A1MAPTKMT2APARP1PARP10
SCHEMBL4168235 0.77 BRD4 (0.41) PARP10SLC9A1HTT
SCHEMBL7123344 0.76 USP2 (0.50) USP2KMT2APARP1CDC7DYRK3
SCHEMBL6157961 0.74 ALDH1A1 (0.71) ALDH1A1MAPTKMT2ANPSR1SLC9A1
SCHEMBL1680735 0.73 MAOB (0.39) MAP4K4MAOBTDP1
SCHEMBL1680812 0.73 HDAC3 (0.38) ALDH1A1MAPTKMT2APPARGPPARA
SCHEMBL1680421 0.73 KDM4E (0.39) ALDH1A1USP2KMT2AMAOBHPGD
SCHEMBL3022624 0.72 PARP10 (0.73) ALDH1A1KMT2APARP1PARP10MAOB
SCHEMBL7061730 0.71 CHRNA7 (0.58) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD ALDH1A1 1926/4885MAPT 4227/4885USP2 4298/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 ALDH1A1 1459/4885MAPT 4111/4885USP2 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.